Development of Folic Acid-Conjugated and Methylene Blue-Adsorbed Au@TNA Nanoparticles for Enhanced Photodynamic Therapy of Bladder Cancer Cells
Overview
Affiliations
Photodynamic therapy (PDT) is a promising treatment for malignancy. However, the low molecular solubility of photosensitizers (PSs) with a low accumulation at borderline malignant potential lesions results in the tardy and ineffective management of recurrent urothelial carcinoma. Herein, we used tannic acid (TNA), a green precursor, to reduce HAuCl in order to generate Au@TNA core-shell nanoparticles. The photosensitizer methylene blue (MB) was subsequently adsorbed onto the surface of the Au@TNA nanoparticles, leading to the incorporation of a PS within the organic shell of the Au nanoparticle nanosupport, denoted as Au@TNA@MB nanoparticles (NPs). By modifying the surface of the Au@TNA@MB NPs with the ligand folate acid (FA) using NH-PEG-NH as a linker, we demonstrated that the targeted delivery strategy achieved a high accumulation of PSs in cancer cells. The cell viability of T24 cells decreased to 87.1%, 57.1%, and 26.6% upon treatment with 10 ppm Au@TNA/MB NPs after 45 min, 2 h, and 4 h of incubation, respectively. We also applied the same targeted PDT treatment to normal urothelial SV-HUC-1 cells and observed minor phototoxicity, indicating that this safe photomedicine shows promise for applications aiming to achieve the local depletion of cancer sites without side effects.
Advances in smart nanotechnology-supported photodynamic therapy for cancer.
Li G, Wang C, Jin B, Sun T, Sun K, Wang S Cell Death Discov. 2024; 10(1):466.
PMID: 39528439 PMC: 11554787. DOI: 10.1038/s41420-024-02236-4.
Fattahi M, Dehghani M, Paknahad S, Rahiminia S, Zareie D, Hoseini B Front Oncol. 2024; 14:1438297.
PMID: 39193389 PMC: 11347329. DOI: 10.3389/fonc.2024.1438297.
Li H, Long G, Tian J Front Oncol. 2023; 13:1255632.
PMID: 37860180 PMC: 10584312. DOI: 10.3389/fonc.2023.1255632.
Hsu C, Cheng N, Liao M, Cheng T, Chiu Y Nanomaterials (Basel). 2023; 13(15).
PMID: 37570591 PMC: 10421507. DOI: 10.3390/nano13152233.
Nanomedicine for Combination Urologic Cancer Immunotherapy.
Tian Y, Liu Z, Wang J, Li L, Wang F, Zhu Z Pharmaceutics. 2023; 15(2).
PMID: 36839868 PMC: 9960671. DOI: 10.3390/pharmaceutics15020546.